देश: ऑस्ट्रेलिया
भाषा: अंग्रेज़ी
स्रोत: Department of Health (Therapeutic Goods Administration)
Laronidase
Genzyme Australasia Pty Ltd
Medicine Registered
VERSION: ALD ANZ A1202-01 SUPERCEDES: ALD ANZ A1104-01 COMMERCIAL Page 1 of 16 ALDURAZYME ® ( laronidase-rch concentrate for solution for infusion ) PRODUCT INFORMATION NAME OF THE MEDICINE ALDURAZYME ® (laronidase), 500 U, concentrate for solution for infusion. CAS No. 210589-09-6 DESCRIPTION ALDURAZYME is produced by recombinant DNA technology and is a replacement therapy for the human enzyme, - L -iduronidase. Purified laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to human - L -iduronidase. The recombinant protein is comprised of 628 amino acids after cleavage of the N-terminus and contains 6 N-linked oligosaccharide modification sites. Laronidase is produced by a genetically engineered Chinese hamster ovary cell line. The protein is purified by a column chromatography process that includes steps to inactivate and remove potential viruses, resulting in a highly purified, active protein. ALDURAZYME is intended for intravenous infusion. It is supplied as a sterile, nonpyrogenic, colourless to pale yellow, clear to slightly opalescent solution that must be diluted prior to administration. The solution has a nominal laronidase concentration of 100 U/mL (0.58 mg/mL) and a pH of approximately 5.5. The extractable volume of 5.0 mL from each vial provides 2.9 mg (500 U) laronidase, 43.9 mg sodium chloride, 63.5 mg monobasic sodium phosphate monohydrate, 10.7 mg dibasic sodium phosphate, and 0.05 mg polysorbate 80. ALDURAZYME does not contain preservatives; vials are for single use only. It is recommended that the diluted solution be filtered through an in - line low protein – binding 0.2μm filter during administration. VERSION: A पूरा दस्तावेज़ पढ़ें